Findings

What do systematic reviews say?

33 questions · 34 findings · 4 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 16 · 47.1%GRADE not reported 0 · 0%Very low 3 · 8.8%Low 6 · 17.6%Moderate 8 · 23.5%High 1 · 2.9%

Leukotriene receptor antagonist vs placebo

Clinical improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Histological improvement (dichotomous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Histological improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Endoscopic improvement (dichotomous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Endoscopic improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Withdrawals due to adverse events · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2.1 [0.21, 21.39]
1 study · 41 participants
Very low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Leukotriene receptor antagonist vs usual care

Exacerbations · autumn asthma exacerbations in children

The review found no eligible studies for this question.

2 findings from 1 review

Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
OR 0.5 [0.17, 1.46]
2 studies · 1326 participants
Low

Leukotriene receptor antagonist vs usual care

Adverse events · autumn asthma exacerbations in children

Leukotriene receptor antagonist showed no clear difference in adverse events compared with usual care (high certainty).

1 finding from 1 review

Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
OR 0.91 [0.63, 1.32]
2 studies · 1326 participants
High

Montelukast vs placebo

Change (improvement) in disease severity (4 to 8 weeks) SMD (modified EASI score and SASSAD) · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 131 participants
Low

Montelukast vs Conventional treatment

Adverse effects (4 to 6 weeks) · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 63 participants
Low

Montelukast vs Conventional treatment

Corticosteroid requirements · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Montelukast vs Conventional treatment

Reduction of pruritus · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Montelukast vs Conventional treatment

Improvement in quality of life · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Montelukast vs Conventional treatment

Need for emollient use · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Montelukast vs placebo

Effect of long‐term control (> 3 months) · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Montelukast vs placebo

Adverse effects (4 to 8 weeks) · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 131 participants
Low

Montelukast vs placebo

Corticosteroid requirements · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Montelukast vs placebo

Reduction of pruritus · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Montelukast vs placebo

Improvement in quality of life · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found